{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T10:13:58Z","timestamp":1778580838876,"version":"3.51.4"},"reference-count":53,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>The association between adalimumab trough levels and disease activity was evaluated in a real-world population with rheumatoid arthritis (RA). The distribution of adalimumab serum levels, proportion of patients with therapeutic exposure to adalimumab, and the presence of antidrug antibodies (ADAs) were explored to determine the utility of therapeutic drug monitoring in RA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A cross-sectional study was conducted among 72 patients with RA who were treated with adalimumab at Maasstad Hospital between May 2022 and March 2023. The adalimumab trough levels and ADAs were measured at the steady state. Disease activity was assessed using the using the Disease Activity Score-28 based on C-reactive protein (DAS28-CRP). Univariable and multivariable regression analyses were conducted to examine the associations between adalimumab levels, disease activity, and clinical covariates, including sex, body mass index, and concomitant methotrexate use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The interindividual variability in the adalimumab trough levels was wide (range: 1.2\u201316 mcg\/mL; median: 5.9 mcg\/mL). No significant association was observed between the adalimumab trough levels and DAS28-CRP scores (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &gt; 0.05). ADAs were present in 13.9% of the patients, and the drug levels were undetectable in 4.2%. The adalimumab trough levels were considerably higher in women than in men (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.05), whereas extended dosing intervals were associated with lower adalimumab concentrations but not with higher disease activity.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>The variability in adalimumab exposure is wide in patients with RA. However, no clear association was observed between adalimumab exposure and disease activity. These findings suggest that therapeutic drug monitoring aids in identifying patients with underexposure or overexposure to adalimumab and support individualized dose optimization, particularly in patients with low disease activity. Future prospective studies are required to evaluate the longitudinal effects of TDM-guided strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001375","type":"journal-article","created":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T12:00:32Z","timestamp":1755777632000},"page":"322-330","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Real-World Adalimumab Trough Levels, Antidrug Antibody Levels, and Disease Activity in Rheumatoid Arthritis"],"prefix":"10.1097","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7102-1090","authenticated-orcid":false,"given":"Juul M.","family":"Cox","sequence":"first","affiliation":[{"name":"Department of Hospital Pharmacy, Maasstad Hospital, Rotterdam, the Netherlands;"},{"name":"Department of Clinical Pharmacology and Toxicology, Maasstad Lab, Maasstad Hospital, Rotterdam, the Netherlands;"},{"name":"Erasmus School of Health Policy and Management, Erasmus University, Rotterdam, the Netherlands;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hazar","family":"El Achaouch","sequence":"additional","affiliation":[{"name":"Utrecht University, Department of Pharmacy, Utrecht University, the Netherlands; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2834-5727","authenticated-orcid":false,"given":"T. Martijn","family":"Kuijper","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Maasstad Hospital, Rotterdam, the Netherlands."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1831-5129","authenticated-orcid":false,"given":"Angelique E. A. M.","family":"Weel-Koenders","sequence":"additional","affiliation":[{"name":"Erasmus School of Health Policy and Management, Erasmus University, Rotterdam, the Netherlands;"},{"name":"Department of Rheumatology and Clinical Immunology, Maasstad Hospital, Rotterdam, the Netherlands."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9337-7784","authenticated-orcid":false,"given":"Tessa M.","family":"Bosch","sequence":"additional","affiliation":[{"name":"Department of Hospital Pharmacy, Maasstad Hospital, Rotterdam, the Netherlands;"},{"name":"Department of Clinical Pharmacology and Toxicology, Maasstad Lab, Maasstad Hospital, Rotterdam, the Netherlands;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,8,21]]},"reference":[{"key":"R1-20260508","doi-asserted-by":"crossref","first-page":"847","DOI":"10.3906\/sag-1603-147","article-title":"Pain, depression levels, fatigue, sleep quality, and quality of life in elderly patients with rheumatoid arthritis","volume":"47","author":"Albayrak Gezer","year":"2017","journal-title":"Turk J Med Sci"},{"key":"R2-20260508","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.amsu.2020.11.043","article-title":"Prevalence of rheumatoid arthritis among hospital workers in the north of Jordan: preliminary report of a hospital-based cohort study","volume":"60","author":"Alawneh","year":"2020","journal-title":"Ann Med Surg (Lond)"},{"key":"R3-20260508","doi-asserted-by":"crossref","first-page":"3458","DOI":"10.1002\/art.20621","article-title":"Do breast-feeding and other reproductive factors influence future risk of rheumatoid arthritis? Results from the nurses' health study","volume":"50","author":"Karlson","year":"2004","journal-title":"Arthritis Rheum"},{"key":"R4-20260508","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.3899\/jrheum.090980","article-title":"Systematic monitoring of disease activity using an outcome measure improves outcomes in rheumatoid arthritis","volume":"37","author":"Katchamart","year":"2010","journal-title":"J Rheumatol"},{"key":"R5-20260508","article-title":"NVR richtlijn reumato\u00efde artritis (RA)","year":"2019"},{"key":"R6-20260508","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"R7-20260508","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1136\/annrheumdis-2018-213502","article-title":"Predictors of disease activity and structural progression after treatment with adalimumab plus methotrexate or continued methotrexate monotherapy in patients with early rheumatoid arthritis and suboptimal response to methotrexate","volume":"77","author":"Smolen","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"R8-20260508","first-page":"1236","article-title":"The effect of dose escalation on the cost-effectiveness of etanercept and adalimumab with methotrexate among patients with moderate to severe rheumatoid arthritis","volume":"26","author":"Incerti","year":"2020","journal-title":"J Manag Care Spec Pharm"},{"key":"R9-20260508","doi-asserted-by":"crossref","first-page":"373","DOI":"10.2217\/pgs.14.178","article-title":"FcGR genetic polymorphisms and the response to adalimumab in patients with rheumatoid arthritis","volume":"16","author":"D\u00e1vila-Fajardo","year":"2015","journal-title":"Pharmacogenomics"},{"key":"R10-20260508","doi-asserted-by":"crossref","first-page":"e38539","DOI":"10.1371\/journal.pone.0038539","article-title":"CD6 and syntaxin binding protein 6 variants and response to tumor necrosis factor alpha inhibitors in Danish patients with rheumatoid arthritis","volume":"7","author":"Krintel","year":"2012","journal-title":"PLoS One"},{"key":"R11-20260508","first-page":"783","article-title":"Genetic markers associated with clinical and radiographic response in adalimumab plus methotrexate- or methotrexate-treated rheumatoid arthritis patients in OPTIMA","volume":"37","author":"Skapenko","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"R12-20260508","doi-asserted-by":"crossref","first-page":"14050","DOI":"10.1038\/s41598-018-32485-0","article-title":"Genetic variant in IL-32 is associated with the ex vivo cytokine production of anti-TNF treated PBMCs from rheumatoid arthritis patients","volume":"8","author":"Damen","year":"2018","journal-title":"Sci Rep"},{"key":"R13-20260508","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1136\/ard.2006.065615","article-title":"Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis","volume":"66","author":"Bartelds","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"R14-20260508","doi-asserted-by":"crossref","first-page":"6656121","DOI":"10.1155\/2021\/6656121","article-title":"Anti-TROVE2 antibody determined by immune-related array may serve as a predictive marker for adalimumab immunogenicity and effectiveness in RA","volume":"2021","author":"Chen","year":"2021","journal-title":"J Immunol Res"},{"key":"R15-20260508","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/RHU.0000000000000229","article-title":"An examination of the mechanisms involved in secondary clinical failure to adalimumab or etanercept in inflammatory arthropathies","volume":"21","author":"Bandr\u00e9s Ciga","year":"2015","journal-title":"J Clin Rheumatol"},{"key":"R16-20260508","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/j.1756-185X.2011.01643.x","article-title":"Decrease of CD68 and MMP-3 expression in synovium by treatment of adalimumab for rheumatoid arthritis","volume":"14","author":"Kanbe","year":"2011","journal-title":"Int J Rheum Dis"},{"key":"R18-20260508","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.cgh.2013.07.010","article-title":"Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases","volume":"12","author":"Roblin","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R19-20260508","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1093\/ibd\/izac030","article-title":"Utility of therapeutic drug monitoring for tumor necrosis factor antagonists and ustekinumab in postoperative Crohn's disease","volume":"28","author":"Pan","year":"2022","journal-title":"Inflamm Bowel Dis"},{"key":"R20-20260508","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00535-016-1266-1","article-title":"Cost-effectiveness of drug monitoring of anti-TNF therapy in inflammatory bowel disease and rheumatoid arthritis: a systematic review","volume":"52","author":"Martelli","year":"2017","journal-title":"J Gastroenterol"},{"key":"R21-20260508","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1080\/1744666X.2019.1630273","article-title":"Therapeutic drug monitoring with biologic agents in immune mediated inflammatory diseases","volume":"15","author":"Papamichael","year":"2019","journal-title":"Expert Rev Clin Immunol"},{"key":"R22-20260508","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1111\/apt.14368","article-title":"Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases","volume":"46","author":"Mitrev","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"R23-20260508","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1186\/s12876-020-01339-3","article-title":"The risk of rheumatoid arthritis among patients with inflammatory bowel disease: a systematic review and meta-analysis","volume":"20","author":"Chen","year":"2020","journal-title":"BMC Gastroenterol"},{"key":"R24-20260508","first-page":"e5695","article-title":"Relationship between ulcerative colitis and rheumatoid arthritis: a review","volume":"11","author":"Attalla","year":"2019","journal-title":"Cureus"},{"key":"R25-20260508","doi-asserted-by":"crossref","first-page":"e079830","DOI":"10.1136\/bmj-2024-079830","article-title":"Proactive therapeutic drug monitoring of biologic drugs in adult patients with inflammatory bowel disease, inflammatory arthritis, or psoriasis: a clinical practice guideline","volume":"387","author":"Kawano-Dourado","year":"2024","journal-title":"BMJ"},{"key":"R26-20260508","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1136\/annrheumdis-2013-204172","article-title":"Key findings towards optimising adalimumab treatment: the concentration-effect curve","volume":"74","author":"Pouw","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"R27-20260508","doi-asserted-by":"crossref","first-page":"rkae030","DOI":"10.1093\/rap\/rkae030","article-title":"Overcoming provider barriers to therapeutic drug monitoring of tumour necrosis factor inhibitors for rheumatoid arthritis: a qualitative analysis","volume":"8","author":"Gavan","year":"2024","journal-title":"Rheumatol Adv Pract"},{"key":"R28-20260508","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1080\/17425255.2017.1353602","article-title":"Clinical utility of therapeutic drug monitoring in biological disease modifying anti-rheumatic drug treatment of rheumatic disorders: a systematic narrative review","volume":"13","author":"Van Herwaarden","year":"2017","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"R29-20260508","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/BOR.0000000000000487","article-title":"Therapeutic drug monitoring of BioLogicals in rheumatoid arthritis: a disconnect between beliefs and facts","volume":"30","author":"Den Broeder","year":"2018","journal-title":"Curr Opin Rheumatol"},{"key":"R30-20260508","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1007\/s10067-025-07307-0","article-title":"Assessing early therapeutic drug monitoring of adalimumab as a predictor of treatment efficacy and immunogenicity in rheumatic diseases: \u201cearly therapeutic drug monitoring of adalimumab\u201d","volume":"44","author":"Ortiz-Fern\u00e1ndez","year":"2025","journal-title":"Clin Rheumatol"},{"key":"R31-20260508","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/acr.23512","article-title":"Medical care costs associated with rheumatoid arthritis in the US: a systematic literature review and meta-analysis","volume":"70","author":"Hresko","year":"2018","journal-title":"Arthritis Care Res"},{"key":"R32-20260508","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1093\/rheumatology\/kead525","article-title":"Adalimumab serum levels and anti-drug antibodies: associations to treatment response and drug survival in inflammatory joint diseases","volume":"63","author":"Jyssum","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"R33-20260508","doi-asserted-by":"crossref","first-page":"e002216","DOI":"10.1136\/rmdopen-2022-002216","article-title":"Therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal disease: a systematic literature review informing EULAR points to consider","volume":"8","author":"Krieckaert","year":"2022","journal-title":"RMD Open"},{"key":"R34-20260508","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1002\/acr.24965","article-title":"Meta-analyses on the effects of disease-modifying antirheumatic drugs on the most relevant patient-reported outcome domains in rheumatoid arthritis","volume":"75","author":"van den Dikkenberg","year":"2023","journal-title":"Arthritis Care Res"},{"key":"R35-20260508","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/bcp.12509","article-title":"Pharmacokinetics and concentration-effect relationship of adalimumab in rheumatoid arthritis","volume":"79","author":"Ternant","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"R36-20260508","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1136\/annrheumdis-2017-211781","article-title":"Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial","volume":"77","author":"L'Ami","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"R37-20260508","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1136\/annrheumdis-2012-201445","article-title":"Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation","volume":"72","author":"van Schouwenburg","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"R39-20260508","doi-asserted-by":"crossref","first-page":"685312","DOI":"10.3389\/fimmu.2021.685312","article-title":"Autoantibodies in rheumatoid arthritis - laboratory and clinical perspectives","volume":"12","author":"R\u00f6nnelid","year":"2021","journal-title":"Front Immunol"},{"key":"R40-20260508","doi-asserted-by":"crossref","first-page":"101729","DOI":"10.1016\/j.jcot.2021.101729","article-title":"Anti-cyclic citrullinated peptide antibody (ACPA) and rheumatoid arthritis: clinical relevance","volume":"24","author":"Iyengar","year":"2022","journal-title":"J Clin Orthop Trauma"},{"key":"R41-20260508","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta25080","article-title":"Enzyme-linked immunosorbent assays for monitoring TNF-alpha inhibitors and antibody levels in people with rheumatoid arthritis: a systematic review and economic evaluation","volume":"25","author":"Tikhonova","year":"2021","journal-title":"Health Technol Assess"},{"key":"R42-20260508","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/jama.2011.406","article-title":"Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up","volume":"305","author":"Bartelds","year":"2011","journal-title":"JAMA"},{"key":"R43-20260508","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1136\/annrheumdis-2014-206588","article-title":"Adalimumab trough concentrations in patients with rheumatoid arthritis and psoriatic arthritis treated with concomitant disease-modifying antirheumatic drugs","volume":"74","author":"Vogelzang","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"R44-20260508","doi-asserted-by":"crossref","first-page":"e13497","DOI":"10.1111\/dth.13497","article-title":"Fluctuations in serum levels of adalimumab and infliximab in patients on stable treatment for psoriasis","volume":"33","author":"Poulsen","year":"2020","journal-title":"Dermatol Ther"},{"key":"R45-20260508","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1177\/0091270009337512","article-title":"Fixed dosing versus body size-based dosing of monoclonal antibodies in adult clinical trials","volume":"49","author":"Wang","year":"2009","journal-title":"J Clin Pharmacol"},{"key":"R46-20260508","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/MIB.0000000000000981","article-title":"Sex is associated with adalimumab side effects and drug survival in patients with Crohn's disease","volume":"23","author":"Lie","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"R47-20260508","doi-asserted-by":"crossref","first-page":"105124","DOI":"10.1016\/j.jbspin.2020.105124","article-title":"Sex differences in clinical characteristics and their influence on clinical outcomes in an observational cohort of patients with rheumatoid arthritis","volume":"88","author":"Shin","year":"2021","journal-title":"Joint Bone Spine"},{"key":"R48-20260508","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1080\/03009742.2019.1602670","article-title":"Association of female sex and positive rheumatoid factor with low serum infliximab and anti-drug antibodies, related to treatment failure in early rheumatoid arthritis: results from the SWEFOT trial population","volume":"48","author":"Hambardzumyan","year":"2019","journal-title":"Scand J Rheumatol"},{"key":"R49-20260508","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/msc.1590","article-title":"Evaluation of a medication optimization intervention and predictors of medication adherence, patient satisfaction and medication adverse events in patients with rheumatoid arthritis","volume":"20","author":"Salt","year":"2022","journal-title":"Musculoskelet Care"},{"key":"R50-20260508","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1136\/ard-2023-224190","article-title":"Cost-utility analysis of tapering strategies of biologicals in rheumatoid arthritis patients in the Netherlands","volume":"82","author":"van Esveld","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"R51-20260508","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1080\/17425255.2017.1320390","article-title":"Prediction of successful dose reduction or discontinuation of adalimumab, etanercept, or infliximab in rheumatoid arthritis patients using serum drug levels and antidrug antibody measurement","volume":"13","author":"Bouman","year":"2017","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"R52-20260508","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1136\/annrheumdis-2017-212376","article-title":"Adalimumab concentration-based tapering strategy: as good as the recommended dosage","volume":"77","author":"Mulleman","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"R53-20260508","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1080\/03009742.2022.2121081","article-title":"Reduced prescription of TNF-inhibitors in chronic arthritis based on therapeutic drug monitoring: a randomized controlled trial","volume":"52","author":"Pfeiffer-Jensen","year":"2023","journal-title":"Scand J Rheumatol"},{"key":"R54-20260508","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12969-023-00930-8","article-title":"Prospective study to characterize adalimumab exposure in pediatric patients with rheumatic diseases","volume":"22","author":"Welzel","year":"2024","journal-title":"Pediatr Rheumatol Online J"},{"key":"R55-20260508","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1136\/annrheumdis-2020-216996","article-title":"Therapeutic drug monitoring of adalimumab in RA: no predictive value of adalimumab serum levels and anti-adalimumab antibodies for prediction of response to the next bDMARD","volume":"79","author":"Ulijn","year":"2020","journal-title":"Ann Rheum Dis"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001375","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T09:42:37Z","timestamp":1778578957000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,21]]},"references-count":53,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001375","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"value":"0163-4356","type":"print"},{"value":"1536-3694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,21]]},"assertion":[{"value":"2025-03-26","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-16","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}